Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Fineline Cube Jun 5, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Fineline Cube Jun 5, 2026
Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Fineline Cube Jun 5, 2026
Company Deals

Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement

Fineline Cube Jul 10, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced a global antibody molecule licensing...

Company Drug

Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment

Fineline Cube Jul 10, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food...

Company Drug

Jiangsu Chia Tai Tianqing’s Culmerciclib Receives NMPA Review for Expanded Breast Cancer Indication

Fineline Cube Jul 10, 2025

Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Deals

Sironax Partners with Novartis on Brain Delivery Module Platform for CNS Drugs

Fineline Cube Jul 10, 2025

China-based biotech innovator Sironax has entered into a strategic agreement with Swiss pharmaceutical giant Novartis...

Company Deals

Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion

Fineline Cube Jul 10, 2025

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU)...

Company Drug

Simcere and Connect Biopharma’s Rademikibart NDA Accepted by China’s NMPA for Atopic Dermatitis

Fineline Cube Jul 10, 2025

The New Drug Application (NDA) for rademikibart, an anti-inflammatory monoclonal antibody (mAb) co-developed by China’s...

Company Deals

Anke Bio Secures Exclusive Rights to Bao Pharma’s Long-Acting FSH-CTP for China Market

Fineline Cube Jul 10, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced an exclusive distribution agreement with...

Company Deals Medical Device

ShuWen Biotech Completes RMB100 Million Series C1 Round to Advance Women’s Health Diagnostics

Fineline Cube Jul 10, 2025

Zhejiang-based ShuWen Biotech Co., Ltd announced the successful completion of an RMB100 million (USD 14...

Company Drug

IASO Biotherapeutics Receives Orphan Drug Designation in South Korea for Fucaso in Multiple Myeloma

Fineline Cube Jul 10, 2025

China-based IASO Biotherapeutics announced that its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Fucaso...

Company Deals

MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio

Fineline Cube Jul 10, 2025

In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant...

Company Drug

Guangdong Taienkang Submits Marketing Application for Generic Vuity to China’s NMPA

Fineline Cube Jul 9, 2025

China-based Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced the submission of a marketing approval...

Company

Pascal Qian Appointed General Manager of BMS China Unit

Fineline Cube Jul 9, 2025

Pascal Qian this week officially assumed the role of General Manager of Bristol-Myers Squibb’s (BMS;...

Company Deals

Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates

Fineline Cube Jul 9, 2025

China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to...

Company Deals

Zhaoke Ophthalmology Partners with Somerset Therapeutics to Accelerate US Expansion

Fineline Cube Jul 9, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced last month a strategic partnership with US generic...

Company Deals

LakeShore Biopharma Secures $15 Million in Private Placement to Fuel Growth

Fineline Cube Jul 9, 2025

China-based biopharmaceutical company LakeShore Biopharma Co., Ltd (NASDAQ: LSB) has announced the successful execution of...

Company Drug

Innovent’s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau

Fineline Cube Jul 9, 2025

China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with...

Company Deals

NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies

Fineline Cube Jul 9, 2025

China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for SHR-2173 in Primary Membranous Nephropathy

Fineline Cube Jul 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Company Drug

J&J Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse

Fineline Cube Jul 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a supplemental New...

Company Drug

Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants

Fineline Cube Jul 9, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic...

Posts pagination

1 … 142 143 144 … 678

Recent updates

  • Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate
  • China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development
  • Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform
  • Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells
  • SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Company Drug

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.